Sabato, 04 Dicembre 2021

Seguici su

"La libertà al singolare esiste solo nelle libertà al plurale"
Benedetto Croce


Veeva Commercial Summit to Spotlight Digital Innovation at Leading Life Sciences Companies

01 Giugno 2021

Experts from Argenx, Boehringer Ingelheim, GSK, Regeneron, Sobi, and UCB to detail strategies for driving commercial agility

BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Boehringer Ingelheim, GSK, and UCB will be among the featured keynote speakers at the 2021 Veeva Commercial & Medical North America Summit Connect on June 10, 2021. They will share the innovative digital approaches and best practices helping their companies maximize commercial impact.

In a fireside chat opening the live online event, Dr. Cecil T. Holbert, M.D., a family medicine practitioner, and Amanda Romano, a diabetes business specialist at Boehringer Ingelheim, will discuss how digital-first engagement enables new ways of working and a better customer experience as healthcare provider (HCP) access evolves.

The event will also feature timely discussions around:

"In the past year, HCP expectations completely changed as the move to digital raised the bar for customer engagement," said Paul Shawah, executive vice president of strategy at Veeva. "This year's Summit Connect will showcase how innovative new digital-first models are transforming customer relationships."

Veeva Summit Connect is one of the largest gatherings for commercial leaders across life sciences to exchange ideas and connect with industry peers. Designed to maximize knowledge sharing through interactive sessions and roundtables, this year's event will feature more than 100 sessions from leaders changing the face of commercial in life sciences.

Life sciences industry professionals can learn more and register at

Additional InformationConnect with Veeva on LinkedIn: @veeva_eu on Twitter: 

About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit

Forward-looking StatementsThis release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-K for the period ended January 31, 2021. This is available on the company's website at under the Investors section and on the SEC's website at Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time. 


Meagan BusathVeeva 

Logo -

Commenti Scrivi/Scopri i commenti

Condividi le tue opinioni su Il Giornale d'Italia

Caratteri rimanenti: 400

Articoli Recenti

Più visti